Table 1.
Clinical Characteristics and Responses of Super-Responders Treated with Anastrozole and Everolimus
| Patient No. | 1 | 2 | 3 |
|---|---|---|---|
| Age at Treatment (years) | 38 | 48 | 44 |
| Date of Diagnosis | August 2009 | September 2007 | September 2010 |
| Date of Biopsy | August 2009 | September 2007 | August 2010 |
| Histology | Ductal | Ductal | Ductal |
| ER Status | 90 % Positive | 95 % Positive | 95 % Positive |
| PR Status | 60 % Positive | 80 % Positive | Negative |
| HER2/neu Status | Negative (FISH) | Negative (FISH) | Negative (IHC) |
| Prior Treatment in Metastatic Setting | Paclitaxel (3 months) 5-fluorouracil, doxorubicin, cyclophosphamide (1 month) Tamoxifen (3 months) Capacitabine ( 3 months) | Tamoxifen (2 months) Paclitaxel, bevacizumaba Vinorelbinea Fulvestrant (3 months) Ixabepilonea Docetaxel (9 months) Docetaxel, doxorubicin, cyclophosphamide (3 months) | Tamoxifen, zoledronic acid (6 months) Letrozole (4 months) |
| Prior Treatment with Aromatase Inhibitor in Metastatic Setting (Duration) | No | No | Yes (4 months) |
| Molecular alterations (Please reference Additional file 1: Table S1) | |||
| Progression Free Survival (months) | 11 | 14 | 9+ |
| Best Response (%) | −56 % | −38 % | −100 % |
aUnknown duration of treatment
FISH Fluorescent in-situ hybridization, IHC Immunohistochemistry